These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33290135)

  • 1. MOG-IgG-associated disorder and systemic lupus erythematosus disease: Systematic review.
    Caroline Breis L; Antônio Machado Schlindwein M; Pastor Bandeira I; Machiavelli Fontana T; Fiuza Parolin L; Weingrill P; Kleinpaul Vieira RG; Vinícius Magno Gonçalves M
    Lupus; 2021 Mar; 30(3):385-392. PubMed ID: 33290135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MOG-IgG myelitis coexisting with systemic lupus erythematosus in the post-partum setting.
    Bilodeau PA; Kumar V; Rodriguez AE; Li CT; Sanchez-Alvarez C; Thanarajasingam U; Zalewski NL; Flanagan EP
    Mult Scler; 2020 Jul; 26(8):997-1000. PubMed ID: 31621483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets?
    Mader S; Jeganathan V; Arinuma Y; Fujieda Y; Dujmovic I; Drulovic J; Shimizu Y; Sakuma Y; Stern JNH; Aranow C; Mackay M; Yasuda S; Atsumi T; Hirohata S; Diamond B
    Arthritis Rheumatol; 2018 Feb; 70(2):277-286. PubMed ID: 29073350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.
    Asgari N; Jarius S; Laustrup H; Skejoe HP; Lillevang ST; Weinshenker BG; Voss A
    Mult Scler; 2018 Mar; 24(3):331-339. PubMed ID: 28326889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD.
    Kunchok A; Flanagan EP; Snyder M; Saadeh R; Chen JJ; Weinshenker BG; McKeon A; Pittock SJ
    Mult Scler; 2021 Apr; 27(4):630-635. PubMed ID: 32633603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
    Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z
    Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
    Tajfirouz DA; Bhatti MT; Chen JJ
    Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
    Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
    Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
    Chen JJ; Bhatti MT
    Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus.
    Pröbstel AK; Thanei M; Erni B; Lecourt AC; Branco L; André R; Roux-Lombard P; Koenig KF; Huynh-Do U; Ribi C; Chizzolini C; Kappos L; Trendelenburg M; Derfuss T;
    Rheumatology (Oxford); 2019 May; 58(5):908-913. PubMed ID: 30265368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
    Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
    Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges.
    Al-Ani A; Chen JJ; Costello F
    J Neurol; 2023 Aug; 270(8):4132-4150. PubMed ID: 37154894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab.
    Shidahara K; Hayashi K; Sada KE; Hiramatsu S; Morishita M; Watanabe H; Matsumoto Y; Kawabata T; Wada J
    Lupus; 2018 Jul; 27(8):1374-1377. PubMed ID: 29498304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association.
    Di Pauli F; Morschewsky P; Berek K; Auer M; Bauer A; Berger T; Bsteh G; Rhomberg P; Schanda K; Zinganell A; Deisenhammer F; Reindl M; Hegen H
    Front Immunol; 2021; 12():769653. PubMed ID: 34737756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases.
    Mader S; Kümpfel T; Meinl E
    Curr Opin Neurol; 2020 Jun; 33(3):362-371. PubMed ID: 32304439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transverse myelitis syndrom as a result of neuromyelitis optica spectrum disorders, systemic lupus erythematosus and myasthenia gravis combination].
    Topuzova MP; Bisaga GN; Alekseeva TM; Isabekova PS; Сhaykovskaya AD; Panina EB; Pavlova TA; Ternovykh IK
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):97-106. PubMed ID: 32844638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.